tiprankstipranks
Trending News
More News >

Chimeric Therapeutics Appoints New Director, Miles Prince

Story Highlights
Chimeric Therapeutics Appoints New Director, Miles Prince

Don’t Miss TipRanks’ Half-Year Sale

Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.

Chimeric Therapeutics Limited has announced the appointment of Miles Prince as a director, effective July 1, 2025. The initial director’s interest notice reveals that Prince currently holds no securities or interests in the company, indicating a fresh start for his involvement. This appointment may influence the company’s strategic direction and strengthen its leadership team as it continues to develop its CAR-T therapies.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies, aiming to address unmet medical needs in oncology.

Technical Sentiment Signal: Sell

Current Market Cap: A$9.07M

Learn more about CHM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1